Angiogénesis
Los inhibidores de la angiogénesis son compuestos que interfieren con la formación de nuevos vasos sanguíneos, un proceso crucial en el crecimiento y la metástasis del cáncer. Al inhibir la angiogénesis, estos compuestos pueden restringir el suministro de sangre a los tumores, ralentizando o deteniendo su crecimiento. Los inhibidores de la angiogénesis son esenciales en la investigación del cáncer y en el desarrollo terapéutico, proporcionando información sobre los mecanismos de progresión tumoral y ofreciendo posibles tratamientos para el cáncer y otras enfermedades relacionadas con la angiogénesis. En CymitQuimica, ofrecemos una amplia gama de inhibidores de la angiogénesis de alta calidad para apoyar su investigación en oncología y biología vascular.
Subcategorías de "Angiogénesis"
- BTK(147 productos)
- Bcr-Abl(103 productos)
- EGFR(572 productos)
- FAK(71 productos)
- FLT(91 productos)
- Receptor del factor de crecimiento de fibroblastos (FGFR)(169 productos)
- JAK(246 productos)
- PDGFR(126 productos)
- RAAS(87 productos)
- Src(80 productos)
- Syk(37 productos)
- Trombina(47 productos)
- VDA(2 productos)
- VEGFR(262 productos)
Mostrar 6 subcategorías más
Se han encontrado 1522 productos de "Angiogénesis"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-34
<p>EGFR-IN-34 is a low-toxicity, acrylamide derivative antitumor agent that is a potent inhibitor of EGFR.</p>Fórmula:C26H27ClN6O2Forma y color:SolidPeso molecular:490.98FAK-IN-23
CAS:<p>FAK-IN-23 (Compound II) is an inhibitor of focal adhesion kinase (FAK).</p>Fórmula:C32H38F3N5O8Forma y color:SolidPeso molecular:677.668HER2-IN-6
CAS:<p>HER2-IN-6, a potent HER2 inhibitor, may target wild/mutant EGFR and HER2-mediated tumors. (Patent WO2021164697A1, compound 11)</p>Fórmula:C26H32N8O3Forma y color:SolidPeso molecular:504.58TGF-βRI inhibitor 3
CAS:<p>TGF-βRI inhibitor 3 (Compound 9ac) is a selective inhibitor of TGF-β that effectively suppresses the TGF-β signaling pathway. It exhibits IC50 values of 13 μM for c-Src kinase and 0.63 μM for ALK5 kinase.</p>Fórmula:C21H21NO4Forma y color:SolidPeso molecular:351.396BMS-066
CAS:BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.Fórmula:C19H21N7O2Pureza:98%Forma y color:SolidPeso molecular:379.42Tyrosine kinase-IN-9
CAS:<p>Tyrosine kinase-IN-9 (Compound B) is an inhibitor of c-Abl. It is useful for studying neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.</p>Fórmula:C20H14ClN3O3Forma y color:SolidPeso molecular:379.796FGFR3-IN-4
CAS:<p>FGFR3-IN-4 is a selective inhibitor targeting FGFR3, demonstrating an IC50 value of under 50 nM.</p>Fórmula:C26H24ClN7OForma y color:SolidPeso molecular:485.97TrxR/EGFR-IN-1
CAS:TrxR/EGFR-IN-1 (Compound L1Au2) is a TrxR/EGFR inhibitor with activity against both gefitinib-sensitive and -resistant lung cancer, effectively suppressing tumor proliferation and promoting apoptosis. It enhances GPX4 degradation through autophagosome-lysosome and proteasome pathways, leading to ferroptosis. Additionally, it induces endoplasmic reticulum stress and triggers immunogenic cell death, making it applicable for studies on gefitinib-resistant lung cancer.Fórmula:C24H24AuClFN6O2PForma y color:SolidPeso molecular:710.878FGFR1 inhibitor-17
CAS:<p>FGFR1inhibitor-17 (Compound 92) is a potent inhibitor of FGFR1, with promising applications in cancer research.</p>Fórmula:C16H13ClN2O3Forma y color:SolidPeso molecular:316.739TZEP7
CAS:<p>TZEP7 functions as an EGFR kinase inhibitor in cancer cells. It exhibits cytotoxicity and induces apoptosis within these cells. TZEP7 downregulates the anti-apoptotic protein Bcl-2, upregulates the pro-apoptotic protein Bax, and increases caspase levels. This compound holds potential for research in anticancer drug development.</p>Fórmula:C27H19ClFNSForma y color:SolidPeso molecular:443.963EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Forma y color:SolidVEGFR-2-IN-16
<p>VEGFR-2-IN-16 (Compound 15b) is a potent inhibitor of VEGFR-2 (IC50: 86.36 nM) that exhibits antitumour effects.</p>Fórmula:C21H13Cl2N3O2Forma y color:SolidPeso molecular:410.25EGFR-IN-23
CAS:<p>EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.</p>Fórmula:C36H44BrN10O3PForma y color:SolidPeso molecular:775.68HSN748
CAS:<p>HSN748 is an analog of ponatinib and acts as a multi-kinase inhibitor. It exhibits inhibitory activity against kinases such as FLT3, ABL1, RET, PDGFRα/β, MNK1, and MNK2. HSN748 can suppress the growth of chronic myeloid leukemia and acute myeloid leukemia cell lines, making it a useful compound in leukemia research.</p>Fórmula:C27H24F3N7OForma y color:SolidPeso molecular:519.521EGFR-IN-24
<p>EGFR-IN-24 is a potent inhibitor of EGFR and inhibits EGFR (del19/T790M/C797S) and EGFR (L858R/T790M/C797S).</p>Fórmula:C30H35FN6O3Forma y color:SolidPeso molecular:546.64Multi-kinase-IN-1
CAS:<p>Multi-kinase-IN-1, a powerful kinase inhibitor, exhibits antitumor properties by inducing cell apoptosis.</p>Fórmula:C35H36F2N6O6SForma y color:SolidPeso molecular:706.76JNJ-47117096
CAS:<p>JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.</p>Fórmula:C21H22N4O2Forma y color:SolidPeso molecular:362.425HER2-IN-9
<p>HER2-IN-9, an oral HER2 inhibitor (IC50: 0.03 μM), hinders growth and spread of HER2+ breast cancer.</p>Fórmula:C19H14BrF3N2OForma y color:SolidPeso molecular:423.23VEGFR/PDGFR-IN-1
CAS:VEGFR/PDGFR-IN-1 (Compound 1) is an inhibitor of VEGFR with an IC50 of 0.4 μM. It can inhibit angiogenesis in HUVEC cells and holds promise for impeding tumor growth and metastasis.Fórmula:C17H21N5O3Forma y color:SolidPeso molecular:343.38BTK-IN-7
<p>BTK-IN-7 is a potent inhibitor for BTK with 4.0 nM IC50, highly selective over ITK and EGFR, showing strong antitumor activity.</p>Fórmula:C30H32N6O4Forma y color:SolidPeso molecular:540.61LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Fórmula:C21H20ClN3O4Forma y color:SolidPeso molecular:413.854EGFR/HER2-IN-6
<p>EGFR/HER2-IN-6 is a dual inhibitor of EGFR, HER2, and DHFR with IC50s: 0.122, 0.078, and 0.585 μM, showing anticancer potential and selectivity.</p>Fórmula:C18H21N5O3SForma y color:SolidPeso molecular:387.46HER2-IN-21
CAS:<p>HER2-IN-21 (compound 657994) is an inhibitor of the human epidermal growth factor receptor 2 (HER2) with an IC50 value of 3.85 μM.</p>Fórmula:C20H18N4O3SForma y color:SolidPeso molecular:394.447FGFR4-IN-6
<p>FGFR4-IN-6: covalent, reversible FGFR4 blocker, 5.4 nM IC50, good oral bioavailability, reduces Hep3B2.1-7 tumors in mice, low toxicity.</p>Fórmula:C31H33N7O4Forma y color:SolidPeso molecular:567.64Protein kinase inhibitor 10
CAS:<p>Protein kinase inhibitor 10 is a protein kinase inhibitor with IC50 values of 28.9 μM, 13.6 μM, and 2.41 μM for TAM receptors, FAK, and KIT, respectively. It can inhibit abnormal and excessive cell proliferation, showing potential for research in the field of cancer treatment.</p>Fórmula:C14H9FN6S2Forma y color:SolidPeso molecular:344.39VEGFR-2-IN-26
CAS:<p>VEGFR-2-IN-26 inhibits VEGFR-2 (IC50: 15.5 nM), combating various cancers' cell growth.</p>Fórmula:C24H19F3N6O2Forma y color:SolidPeso molecular:480.44FGFR4-IN-9
<p>FGFR4-IN-9 is a selective inhibitor of FGFR4 (IC50: 75.3 nM) that effectively inhibits the growth and angiogenesis of hepatocellular carcinoma cells.</p>Fórmula:C24H22ClF3N4O4Forma y color:SolidPeso molecular:522.9PF-06263276
CAS:<p>PF-06263276 selectively inhibits pan-JAK with IC50: JAK1 (2.2 nM), JAK2 (23.1 nM), JAK3 (59.9 nM), TYK2 (29.7 nM).</p>Fórmula:C31H31FN8O2Pureza:98%Forma y color:SolidPeso molecular:566.63EGFR-IN-161
CAS:<p>EGFR-IN-161 (Compound DD-8) is a potent and reversible inhibitor of the L858R/T790M/C797S mutant EGFR kinase, with an IC50 value of 0.87 nM. EGFR-IN-161 effectively inhibits tumor cell apoptosis, G1 phase arrest, and migration.</p>Fórmula:C33H36Cl2N8O2Forma y color:SolidPeso molecular:647.597Dual Cathepsin L/JAK-IN-1
CAS:<p>DualCathepsinL/JAK-IN-1 (Compound A8) serves as a dual inhibitor of Cathepsin L (CTSL) and JAK, exhibiting IC50 values of 0.68 μM for CTSL and 337.1 nM, 5.251 nM, 27.29 nM, and 172.6 nM for JAK1/2/3 and TYK2, respectively. This compound effectively prevents the activation of MAPK, NF-κB, and JAK/STAT signaling pathways, leading to significant anti-inflammatory therapeutic effects. DualCathepsinL/JAK-IN-1 is applicable in research on acute lung injury (ALI).</p>Fórmula:C19H18ClN5Forma y color:SolidPeso molecular:351.833MM-589 TFA
CAS:<p>MM-589 TFA is a potent WD repeat domain 5 (WDR5)inhibitor and mixed lineage leukemia (MLL) protein-protein interaction.</p>Fórmula:C30H45F3N8O7Pureza:98%Forma y color:SolidPeso molecular:686.72RGB-286638
CAS:<p>RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.</p>Fórmula:C29H37Cl2N7O4Forma y color:SolidPeso molecular:618.55EGFR-IN-17
<p>EGFR-IN-17: potent, selective EGFR inhibitor, IC50 of 0.2 nM, overcomes C797S drug resistance.</p>Fórmula:C27H31ClN7O3PForma y color:SolidPeso molecular:568.01E7090 succinate
CAS:<p>E7090 succinate inhibits FGFR1, FGFR2, and FGFR3 with IC50: 0.71, 0.50, 1.2 nM; less so FGFR4 at 120 nM.</p>Fórmula:C76H92N10O24Forma y color:SolidPeso molecular:1529.60ALK-IN-31
CAS:<p>ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).</p>Fórmula:C30H33N5O2SForma y color:SolidPeso molecular:527.68CLM3
CAS:<p>CLM3, a pyrazolopyrimidine derivative, functions as a multitargeted tyrosine kinase inhibitor. It exhibits antiproliferative and proapoptotic activities on endothelial and cancer cells, activities that are synergistically enhanced by SN38. The primary mechanism of action for CLM3 involves the inhibition of phosphorylation in tyrosine kinases such as VEGFR-2, EGFR, and RET, along with their associated signaling pathways.</p>Fórmula:C21H21N5Forma y color:SolidPeso molecular:343.43SYHA1815
CAS:SYHA1815, an orally active RET inhibitor (IC50=0.9 nmol/L), demonstrates antitumor activity. It exhibits greater selectivity for RET over KDR (IC50=15.9 nmol/L). SYHA1815 operates by downregulating c-Myc, arresting the G1 cell cycle, and inhibiting RET-driven cell proliferation.Fórmula:C27H26ClF4N5OForma y color:SolidPeso molecular:547.98Protein Kinase Inhibitor 12
CAS:<p>Protein Kinase Inhibitor 12 (compound 1-91) is protein kinase inhibitor,PIM-1, CDK-2, GSK-3, and SRC mammalian protein kinases.</p>Fórmula:C14H14N4OSPureza:98.06%Forma y color:SolidPeso molecular:286.35Anticancer agent 69
<p>Anticancer agent 69 targets PC3 cells (IC50=26 nM), raises ROS, lowers EGFR, and induces apoptosis.</p>Fórmula:C19H26N8SForma y color:SolidPeso molecular:398.53Multi-kinase inhibitor 3
CAS:<p>Multi-kinase inhibitor 3 (compound 12) is an orally active and effective multikinase (multikinase) inhibitor, demonstrating potent IC50 values against FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, and PDGFRβ, at 1.59, 1.23, 1.19, 0.59, 0.22, and 1.15 nM respectively. This compound exhibits anti-proliferative and anticancer activities.</p>Fórmula:C26H26N6O2Forma y color:SolidPeso molecular:454.52Antiallergic agent-1
<p>Antiallergic agent-1, an Src family kinase inhibitor, is a new and valuable lead compound with potential as an anti-allergic agent.</p>Fórmula:C27H19F6N5OForma y color:SolidPeso molecular:543.46EGFR-IN-58
<p>EGFR-IN-58 is a potent, selective, ATP-competitive inhibitor of EGFR. EGFR-IN-58 exhibits significant cytotoxicity against melanoma, colon and blood cancers.</p>Fórmula:C31H30FN7OForma y color:SolidPeso molecular:535.61SILA-123
CAS:<p>SILA-123, an inhibitor of FLT3 (FLT3-WT: IC50=2.1 nM; FLT3-ITD: IC50=1.0 nM), induces cell apoptosis by hindering the cell cycle progression at the G0/G1 phase through the suppression of FLT3 phosphorylation and its downstream signaling pathways. This compound is utilized in the study of acute myeloid leukemia.</p>Fórmula:C24H25N5O2Forma y color:SolidPeso molecular:415.49RET-IN-14
CAS:<p>RET-IN-14 inhibits RET (IC50: <0.51-9.3 nM) & BTK (C481S) (IC50: 9.2-15 nM), promising for tumor research.</p>Fórmula:C24H23FN8O4Forma y color:SolidPeso molecular:506.49I194496
CAS:<p>I194496 is an effective inhibitor of cystathionine γ-lyase (CSE) with an IC50 value of 0.79 mM. It inhibits the growth of human TNBC cells by dual targeting the PI3K/Akt and Ras/Raf/ERK pathways. Additionally, I194496 suppresses the metastasis of human TNBC cells by downregulating the Anxa2/STAT3 and VEGF/FAK/Paxillin signaling pathways.</p>Fórmula:C28H23F2N5O5SForma y color:SolidPeso molecular:579.58JAK3/BTK-IN-4
CAS:<p>JAK3/BTK-IN-4, a dual inhibitor for JAK3/BTK, shows synergy in autoimmune disease treatment. (Patent WO2021147953A1, compound 003)</p>Fórmula:C21H25ClN8OForma y color:SolidPeso molecular:440.93FAK-IN-6
<p>FAK-IN-6: Potent FAK inhibitor (IC50=1.415 nM), anti-cancer, for pancreatic studies.</p>Fórmula:C25H31ClN5O6PSForma y color:SolidPeso molecular:596.04VEGFR-2/DHFR-IN-1
<p>Compound 8b inhibits VEGFR-2/DHFR, combats various bacteria, and fights cancer cells.</p>Fórmula:C20H18ClNO4Forma y color:SolidPeso molecular:371.81YSY01A
CAS:<p>YSY01A is a proteasome inhibitor that suppresses cancer cell survival by inducing apoptosis (Apoptosis). It demonstrates IC50 values against various cell lines such as HEK293T, A549, MCF-7, MGC-803, and PC-3M with values of 51.01, 9.21, 5.21, 8.9, and 35.4 nM respectively. Additionally, YSY01A serves as a degrader of gp130 and JAK2, eliminating constitutive STAT3 signaling in human A549 lung cancer cells by downregulating gp130 and JAK2. YSY01A holds potential for research in cancer therapeutics.</p>Fórmula:C29H38BN5O5Forma y color:SolidPeso molecular:547.45EGFR-IN-125
CAS:<p>EGFR-IN-125 (example 37) is a potent EGFR inhibitor with IC50 values of <0.3 nM for EGFR(d746-750/T790M/C797S), 0.52 nM for EGFR(L858R/T790M/C797S), 0.5 nM for EGFR(d746-750/C797S), 0.69 nM for EGFR(L858R/C797S), and 0.92 nM for EGFR (wild type).</p>Fórmula:C30H26N8OForma y color:SolidPeso molecular:514.58
